PRECIRIX® is a private biotechnology company dedicated to extending and improving the lives of cancer patients by designing and developing precision radiopharmaceuticals, using camelid single-domain antibodies (sdAb) labelled with radiometals.
The company’s lead program targets Fibroblast Activation Protein (FAP) and is transitioning into the clinic. It has the potential to be the first in class alpha-emitting targeted radiotherapy against the pan tumor target FAP. Research on multiple isotopes, linker technology and combination therapies is ongoing to further expand the platform.